The drug exhibits a multimodal mechanism. It not only reverses chemoresistance and halts tumor growth but also 'turns cold tumors hot' by forcing cancer cells to display markers that make them visible to the immune system. This dual action of direct attack and immune activation creates a powerful synergistic effect.

Direxonrasib is showing unprecedented response rates (e.g., 47% in frontline) for metastatic pancreatic cancer, a historically difficult-to-treat disease. This high performance prompts comparisons to the targeted therapy successes seen in lung cancer, signaling a potential paradigm shift in treatment expectations for PDAC.

TAMP is delivered once every two weeks, but crucially, patients generally do not receive other treatments concurrently. This regimen provides significant breaks from therapy, helping to preserve pre-procedural quality of life—a major advantage over the continuous burden of systemic chemotherapy.

TAMP uses a unique double-balloon catheter to isolate an arterial segment. This pressure-mediated delivery forces chemotherapy across the vessel wall directly into the tumor, overcoming the washout effect that caused previous intra-arterial therapies to fail.

A leading hypothesis for why adding immunotherapy to chemoradiation failed is that radiation, particularly for central tumors, destroys the very lymphocytes immunotherapy aims to activate. This biological mechanism suggests the radiation essentially canceled out the drug's intended effect.

Unlike systemic treatments, which rarely cause pancreatic tumors to shrink on scans, TAMP is demonstrating meaningful radiographic responses. This includes resolving major vessel narrowing, suggesting a more potent local effect and hinting at its potential for converting patients to resectability.

Historically, intratumoral therapy was limited by the physical difficulty of reaching tumors. The rise of a new discipline, Interventional Oncology, has largely solved this access problem. The critical bottleneck is now the lack of drugs specifically designed and optimized for local delivery and sustained retention within the tumor.

Rather than expecting cell therapies (CAR-T, TIL) to eradicate every cancer cell, Dr. Radvanyi reframes them as powerful adjuvants. Their role is to inflict initial damage, kill tumor cells, and release antigens, creating an opportunity to prime a broader, secondary immune response with other modalities like vaccines or checkpoint inhibitors.

Unlike VEGF TKIs that primarily target the tumor vasculature, the HIF-2 inhibitor belzutifan has a direct anti-tumor cell effect. This mechanism may be uniquely effective against micrometastatic disease, following the logic of traditional chemotherapy. This distinction could explain its surprising success in the adjuvant setting where multiple VEGF TKIs have failed.